Post the global outbreak of the monkeypox disease in early 2022, there has been a surge in interest towards research for effective and safe vaccines / therapeutics intended for the management / treatment of disease symptoms
Roots Analysis has announced the addition of Monkeypox Treatment Market report to its list of offerings.
Given the increase in research and development activity in this domain and the substantial financial assistance provided by public funding institutes, the monkeypox therapeutics / vaccines and diagnostic kits market is projected to grow at a steady pace in the near future.
To order this 175+ page report, which features 120+ figures and 130+ tables, please visit https://www.rootsanalysis.com/reports/monkeypox-treatment-market.html
More than 20% of the aforementioned candidates are approved or have been granted expanded access for the treatment / prevention of monkeypox. Further, 70% of the total candidates are in preclinical stages of development. It is also worth noting that ~65% of the candidates in development pipeline are biologics.
Interestingly, nearly 65% of the diagnostic kit providers are based in Asia-Pacific and rest of the world. Notably, around 50% of the total players engaged in this space are mid-sized firms. Additionally, over 75% of monkeypox diagnostic kits use polymerase chain reaction (PCR) as a detection method.
More than 85% of the partnerships were inked in the year 2022, indicating the recent surge in interest of industry stakeholders in this domain. Further, majority of the deals were supply agreements (75%), and primarily focused on expanding their global reach.
Close to 40% of the total amount was awarded under the R01 mechanism (which supports research projects). Further, microbiology / immunology / virology departments emerged as the key research departments, having received over 35% of the total grants.
35% of the articles published in this domain were research papers, followed by review papers (12%). It is important to note that close to 90% of the total articles were published post-2020, highlighting the growing research activity in the recent years.
The monkeypox therapeutics / vaccines market’s evolution is likely to be driven by the rising need for novel drug candidates. In terms of type of product, vaccines are expected to occupy a larger share (99%) of the overall monkeypox therapeutics and vaccines market in 2035.
In the long term, hospitals and clinics are likely to contribute to a majority share (~50%) of revenues as end users. Further, North America and Europe are anticipated to capture close to 70% share of the monkeypox diagnostic kits market.
You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/monkeypox-treatment-market/request-sample.html
The financial opportunity within the within the monkeypox therapeutics / vaccines and diagnostic kits market has been analyzed across the following segments:
The opinions and insights presented in the report were influenced by discussions held with multiple stakeholders in this domain. According to industry experts the monkeypox therapeutics / vaccines and diagnostic kits market is likely to grow over the coming years if the disease becomes a pandemic. The report features detailed transcripts of interviews held with the following industry stakeholders:
The research also includes detailed profiles of key players (listed below) engaged in the monkeypox therapeutics / vaccines and diagnostic kits markets; each profile features a brief overview of the company, details related to its product portfolio (therapeutics / vaccines or diagnostic kits), recent developments and an informed future outlook.
For additional details, please email at sales@rootsanalysis.com
Contact:
Gaurav Chaudhary
Gaurav.chaudhary@rootsanalysis.com
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner
SUBSCRIBE TO INDUSTRY UPDATES